Clinical trialsCompany release

Ovid Therapeutics reports Q3 update: OV329 trials advance, OV4071 data due Q1 2027

🇺🇸 Ovid Therapeutics Inc. (OVID) · Tue 10 Nov 2026

The US biotech says its cash of $161.4 million should fund operations into 2029 as it progresses two epilepsy-focused programmes.

Ovid Therapeutics gave a third-quarter 2026 business update on 10 November, reporting progress across its neurology pipeline and a cash position of $161.4 million at 30 September 2026. The company expects this to fund its runway into 2029.

OV329 is being tested in a Phase 2 study in treatment-resistant focal epilepsy, with a readout expected in the second half of 2027. A separate photosensitivity study of the compound is due to deliver topline results in the first quarter of 2027.

Ovid also plans to begin a study of a paediatric formulation of OV329 in seizures associated with tuberous sclerosis complex (TSC) before the end of 2026. The start depends on regulatory clearances, which the company has not yet reported as received.

The oral KCC2 activator OV4071 is in a Phase 1 study, with topline data expected in the first quarter of 2027. Ovid said no serious adverse events have been reported so far.

What it means for your team

  • Two near-term readouts are due in Q1 2027: the OV329 photosensitivity study and the OV4071 Phase 1 study.
  • The paediatric TSC study of OV329 is contingent on regulatory clearances, so its start before year-end 2026 is not yet confirmed.
  • The reported absence of serious adverse events in the OV4071 Phase 1 study is an early safety observation only; full data are due with the topline results.
  • The runway into 2029 covers the expected OV329 Phase 2 focal epilepsy readout in H2 2027.

Company's press release (SEC filing): Ovid Therapeutics Inc. ↗

Article written by VigiEye from the official source (Ovid Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →